vonapanitase (PRT-201) / Protara Therap - LARVOL DELTA

PATENCY-2 trial of vonapanitase to promote radiocephalic fistula use for hemodialysis and secondary patency. (PubMed, J Vasc Access) - P3 | "Vonapanitase was well-tolerated and safe. clinicaltrials.gov: NCT02414841 (https://clinicaltrials.gov/ct2/show/NCT02414841)."

Clinical • Journal

"$PRTO Receives FDA Breakthrough Therapy Designation for Vonapanitase" - BioStocks

Biosimilar

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2) (clinicaltrials.gov) - P3; N=696; Completed; Sponsor: Proteon Therapeutics; Active, not recruiting ➔ Completed; Trial completion date: Feb 2021 ➔ May 2019

Clinical • Trial completion • Trial completion date

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Proteon Therapeutics; N=30 ➔ 0; Active, not recruiting ➔ Withdrawn

Clinical • Enrollment change • Monotherapy • Trial withdrawal

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK) (clinicaltrials.gov) - P1; N=29; Completed; Sponsor: Proteon Therapeutics; Active, not recruiting ➔ Completed

Clinical • Trial completion

A randomized trial of vonapanitase (PATENCY-1) to promote radiocephalic fistula patency and use for hemodialysis. (PubMed, J Vasc Surg) - "Vonapanitase treatment did not significantly improve primary patency but was associated with increased secondary patency and use for hemodialysis. Further research is needed to evaluate these end points."

Clinical • Journal

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries (clinicaltrials.gov) - P1; N=30; Active, not recruiting; Sponsor: Proteon Therapeutics; Not yet recruiting ➔ Active, not recruiting; Trial completion date: Dec 2019 ➔ Apr 2019; Trial primary completion date: Dec 2019 ➔ Apr 2019

Clinical • Enrollment closed • Monotherapy • Trial completion date • Trial primary completion date

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK) (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: Proteon Therapeutics; Recruiting ➔ Active, not recruiting; Trial completion date: Jan 2020 ➔ Apr 2019

Clinical • Enrollment closed • Trial completion date

A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1) (clinicaltrials.gov) - P3; N=300; Completed; Sponsor: Proteon Therapeutics; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2) (clinicaltrials.gov) - P3; N=600; Active, not recruiting; Sponsor: Proteon Therapeutics; Trial primary completion date: Feb 2021 ➔ Feb 2018

Clinical • Trial primary completion date

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: Proteon Therapeutics; Trial primary completion date: Dec 2018 ➔ Dec 2019

Clinical • Monotherapy • Trial primary completion date

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2) (clinicaltrials.gov) - P3; N=600; Active, not recruiting; Sponsor: Proteon Therapeutics; Trial primary completion date: Feb 2019 ➔ Feb 2021

Clinical • Trial primary completion date

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK) (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Proteon Therapeutics; Trial primary completion date: Dec 2018 ➔ Jun 2019

Clinical • Trial primary completion date